{"id":39655,"date":"2013-10-31T17:17:22","date_gmt":"2013-10-31T21:17:22","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=voices&#038;p=39655"},"modified":"2013-10-31T17:17:22","modified_gmt":"2013-10-31T21:17:22","slug":"does-optimize-reveal-the-optimal-dapt-time-frame","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2013\/10\/31\/does-optimize-reveal-the-optimal-dapt-time-frame\/","title":{"rendered":"Does OPTIMIZE Reveal the Optimal DAPT Time Frame?"},"content":{"rendered":"<p>In <a href=\"http:\/\/jama.jamanetwork.com\/article.aspx?articleid=1765224\">the OPTIMIZE trial<\/a> of 3119 patients with stable coronary artery disease or low-risk ACS treated with zotarolimus-eluting stents, 3 months of dual antiplatelet therapy (DAPT) was noninferior to 12 months for net adverse clinical and cerebral events (composite of all-cause death, MI, stroke, or major bleeding) without significantly increasing the risk of stent thrombosis. Tell us:<\/p>\n<ul>\n<li><strong>In what percentage of your PCI cases do you use a zotarolimus stent? <\/strong><\/li>\n<\/ul>\n<ul>\n<li><strong>Are the results unique to the zotarolimus-eluting DES or applicable to other second generation (i.e., everolimus-eluting) DES? <\/strong><\/li>\n<\/ul>\n<ul>\n<li><strong>Does this study persuade you to administer DAPT for 3 months rather than 12 months to low-risk patients treated with a DES?<\/strong><\/li>\n<\/ul>\n<p>To read more about OPTIMIZE, click <a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/prolonged-dual-antiplatelet-therapy-may-not-be-necessary-for-second-generation-drug-eluting-stents\/\">here<\/a> for our news story.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rick Lange and David Hillis pose several important questions triggered by the OPTIMIZE findings.<\/p>\n","protected":false},"author":214,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[495,1,9],"tags":[821,861,2041],"class_list":["post-39655","post","type-post","status-publish","format-standard","hentry","category-anticoagulation-2","category-general","category-interventional-cardiology","tag-drug-eluting-stents","tag-dual-antiplatelet-therapy","tag-optimize"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/39655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/214"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=39655"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/39655\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=39655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=39655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=39655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}